Funding
Action Pharma A/S has completed a financing round of €5 million to fund ongoing Phase IIa studies, and the initiation of a Phase IIb study of AP214 for protection against acute kidney injury in patients undergoing cardiac surgery under cardiopulmonary bypass.
“The recent financing round shows strong continued support from our current shareholders. Further, the additional financing puts the company into a strong position to execute on the coming key trials for AP214,” says Ingelise Saunders, CEO of Action Pharma.
Existing shareholders taking part in the round were Sunstone Capital, Global Life Science Ventures, SLS Invest and InnovationsKapital.
Receive our Policy Bulletin each Tuesday & Thursday and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
